The process of angiogenesis is well described for its potential role in the development of
normal ovaries, and physiological functions as well as in the initiation, progression, and …

(1) Background: Among new anti-angiogenesis agents being developed and ever-changing
guidelines indications, the question of the benefits/safety ratio remains unclear.(2) Methods …

Introduction High-grade serous ovarian carcinoma (HGSC) is an aggressive subtype of
epithelial ovarian carcinoma (EOC) and remains the most lethal gynecologic cancer. A lack …

Background There are a variety of treatment options for recurrent platinum-resistant ovarian
cancer, and the optimal specific treatment still remains to be determined. Therefore, this …

Background As the development of novel anti-angiogenic drugs and the continuous
evolution of guideline recommendations, the efficacy and safety of anti-angiogenic agents in …

Background Many women, and other females, with epithelial ovarian cancer (EOC) develop
resistance to conventional chemotherapy drugs. Drugs that inhibit angiogenesis …

Concerns increase with maintenance therapy for advanced urothelial cancer (aUC). We
perform a comprehensive network meta-analysis (NMA) to investigate the efficacy and …

Background Currently, the optimal adjuvant regional nodal irradiation (RNI) volume for
breast cancer (BC) remained controversial. We aimed to define the optimal RNI treatment …

Bevacizumab for Recurrent Platinum-Sensitive Ovarian Cancer: CADTH Health Technology
Review - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC …

Bevacizumab for Recurrent Platinum-Sensitive Ovarian Cancer - NCBI Bookshelf US flag
An official website of the United States government Here's how you know NIH NLM Logo …